Fol­low­ing in­jec­tion side ef­fects, De­sign Ther­a­peu­tics to re­for­mu­late Friedre­ich's atax­ia drug, de­lay tri­al time­line

De­sign Ther­a­peu­tics said Tues­day morn­ing that it was plan­ning to re­for­mu­late its Friedre­ich’s atax­ia drug fol­low­ing in­jec­tion site re­ac­tions in a Phase I study.

As a re­sult, De­sign has de­layed its clin­i­cal tri­al plans sub­stan­tial­ly — the Carls­bad, CA biotech said it now plans to be­gin a new mul­ti­ple-dose Phase I study in the sec­ond half of 2024, with ini­tial da­ta in 2025. Pre­vi­ous­ly in May, De­sign had guid­ed that it ex­pect­ed to start a Phase II study in Friedre­ich’s atax­ia in the sec­ond half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER